Pleione bulbocodioides Polysaccharides Reprogram Tumor-Associated Macrophages via JAK2/STAT3 Inhibition to Suppress Hepatocellular Carcinoma
Journal of Hepatocellular Carcinoma · 2026-03 · Volume 13 · 1-16
DOI: 10.2147/jhc.s578276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-03. Verfasst von Yongjia Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Dunhuang Medicine, Ministry of Education, Gansu University of Chinese Medicine, Lanzhou, Gansu, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Tumor-associated macrophages (TAMs) are key regulators of the immunosuppressive tumor microenvironment in hepatocellular carcinoma (HCC). Sustained activation of the JAK2/STAT3 signaling pathway is closely associated with the maintenance of the pro-tumorigenic M2 macrophage phenotype. Pleione bulbocodioides polysaccharides (PBPs) have been reported to exhibit immunomodulatory and antitumor activities; however, whether PBPs regulate TAM polarization in HCC and the involvement of JAK2/STAT3 signaling remain unclear.
Methods
The monosaccharide composition and molecular-weight distribution of PBPs were first characterized. Their immunomodulatory effects were evaluated in vitro using IL-4/IL-13-induced M2-polarized RAW264.7 macrophages. In vivo, a Hepa1-6 tumor-bearing mouse model was established to assess the effects of PBPs on tumor growth, intratumoral macrophage composition, and JAK2/STAT3 signaling. The JAK2/STAT3 inhibitor AG490 was included as a pharmacological reference.
Results
PBPs were identified as high-molecular-weight polysaccharides predominantly composed of mannose and glucose and exhibited no cytotoxicity toward macrophages within the tested concentration range. In vitro, PBPs attenuated M2-associated marker expression and reduced the secretion of immunosuppressive cytokines, including interleukin-10 and transforming growth factor-β. In Hepa1-6 tumor-bearing mice, PBPs dose-dependently suppressed tumor growth and remodeled intratumoral macrophage composition, characterized by a decrease in M2 macrophages and a concomitant increase in M1 macrophages. These effects were accompanied by suppressed JAK2/STAT3 signaling and coordinated regulation of apoptosis- and angiogenesis-related factors.
Conclusion
PBPs suppress HCC progression in association with modulation of TAM polarization and inhibition of JAK2/STAT3 signaling. These findings provide mechanistic insight into the immunomodulatory actions of PBPs and support their further investigation as macrophage-targeting agents for HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Dunhuang Medicine, Ministry of Education, Gansu University of Chinese Medicine, Lanzhou, Gansu, People's Republic of China.
- The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou, Gansu, People's Republic of China.
- Clinical Medical College, Hubei College of Chinese Medicine, Jingzhou, Hubei, People's Republic of China.
- Beihai Hospital of Traditional Chinese Medicine, Beihai, Guangxi, People's Republic of China.
Zitieren
APA
Yang, Y., Zhang, Y., Feng, X., Gao, F., Ma, Y., & Yang, S. (2026). Pleione bulbocodioides Polysaccharides Reprogram Tumor-Associated Macrophages via JAK2/STAT3 Inhibition to Suppress Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, Volume 13, 1-16. https://doi.org/10.2147/jhc.s578276
Vancouver
Yang Y, Zhang Y, Feng X, Gao F, Ma Y, Yang S. Pleione bulbocodioides Polysaccharides Reprogram Tumor-Associated Macrophages via JAK2/STAT3 Inhibition to Suppress Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-16. doi:10.2147/jhc.s578276
BibTeX
@article{Yang2026,
author = {Yang, Yongjia and Zhang, Yujie and Feng, Xiaoyan and Gao, Fen and Ma, Yanhua and Yang, Shaojun},
title = {Pleione bulbocodioides Polysaccharides Reprogram Tumor-Associated Macrophages via JAK2/STAT3 Inhibition to Suppress Hepatocellular Carcinoma},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--16},
doi = {10.2147/jhc.s578276}
}
EUVIMED